Tag: intravenous iron drugs market share

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Intravenous Iron Drugs Industry Compare Between 2025 And 2029?

The market for intravenous iron drugs has experienced substantial growth in recent years. This market is projected to expand from $3.44 billion in 2024 to $3.81 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. Historically, this expansion has been driven by factors such as the increasing prevalence of iron deficiency anemia, a rising occurrence of chronic diseases, growing healthcare expenditures, an aging global population, and a higher incidence of relevant target illnesses.

The intravenous iron drugs market size is set to experience significant expansion over the next few years. It is projected to reach $5.73 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.8%. This anticipated growth during the forecast period can be primarily linked to government initiatives, ongoing research and development within the realm of IV iron drugs, an escalating demand for intravenous iron medicines, a growing number of research and development activities, and advancements in administration and formulation. Noteworthy trends anticipated in the forecast period include advanced intravenous iron therapies, progress in drug development, a move towards more convenient IV iron therapies, strategic collaborations, partnerships, and acquisitions, alongside innovations in novel drug delivery systems.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

Which Factors And Drivers Are Influencing The Intravenous Iron Drugs Market In 2025?

The rising prevalence of chronic kidney disease (CKD) is anticipated to propel the growth of the intravenous iron drugs market in the future. CKD refers to the progressive loss of kidney function over time, leading to the kidneys’ diminished capacity to effectively filter waste and excess fluids from the blood. This increasing occurrence of chronic kidney disease (CKD) results from higher rates of diabetes and hypertension, which contribute to kidney deterioration over time. Intravenous iron medications assist chronic kidney disease patients by replenishing iron stores, correcting anemia, and improving hemoglobin levels, which enhances oxygen transport and reduces the need for erythropoiesis-stimulating agents. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease (CKD) mortality rates increased by 4.2% in 2021 and 6.2% in 2022. In 2022, CKD was responsible for approximately 22,000 deaths in Australia, constituting 11% of all fatalities. Therefore, the growing incidence of chronic kidney disease (CKD) is a key driver for the expansion of the intravenous iron drugs market.

What Are The Key Segments In The Intravenous Iron Drugs Market?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

What Trends Are Expected To Drive The Intravenous Iron Drugs Market?

Leading companies in the intravenous iron drugs market are channeling their efforts into developing innovative treatments, such as intravenous (IV) iron replacement therapy, to enhance efficacy, safety, and patient outcomes. Intravenous (IV) iron replacement therapy represents a medical procedure that directly administers iron into the bloodstream via an intravenous infusion. This therapeutic approach addresses iron deficiency and anemia, particularly benefiting patients who are unable to tolerate or adequately absorb oral iron supplements. For example, in June 2023, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company specializing in pioneering drug development and healthcare solutions, declared that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for the management of iron deficiency in adult patients with heart failure categorized as New York Heart Association class II/III, aiming to improve exercise capacity. Injectafer is a widely employed intravenous iron therapy recognized for its rapid replenishment of iron levels in individuals who cannot tolerate or respond inadequately to oral iron supplements.

Which Industry Leaders Are Driving Innovation Across The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Intravenous Iron Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Browse Through More Reports Similar to the Global Intravenous Iron Drugs Market 2025, By The Business Research Company

Iron Ore Pellets Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iron-ore-pellets-global-market-report

Iron And Steel Mills And Ferroalloy Market 2025

https://www.thebusinessresearchcompany.com/report/iron-and-steel-mills-and-ferroalloy-market

Iron And Steel Casting Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/iron-and-steel-casting-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What CAGR And Valuation Are Anticipated For The Intravenous Iron Drugs Market?

The market size of intravenous iron drugs has seen a significant increase in the past few years. It is projected to rise from $3.44 billion in 2024 to $3.81 billion in 2025, with a compound annual growth rate (CAGR) of 10.6%. Factors such as the growing occurrence of iron deficiency anemia, an upsurge in chronic diseases, an increase in healthcare expenditure, an aging population, and increased incidents of target diseases have driven growth during the historic period.

Expectations for the intravenous iron drugs market size suggest a swift expansion within the coming years. By 2029, the valuation could reach $5.73 billion, with a compound annual growth rate (CAGR) of 10.8%. Numerous factors contribute to this anticipated growth in the forecast period, testament to government initiatives, developments in research for IV iron drugs, rising demand for intravenous iron medications, an increase in the scope for research and development activities, along with enhancements in administration and formulation. Several trends are set to shape the forecast period, such as the introduction of superior intravenous iron therapies, progress in drug development, the leaning towards more user-friendly IV iron therapies, tactful collaborations, partnerships and takeovers, as well as novel drug delivery system innovations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Are The Primary Factors Supporting The Intravenous Iron Drugs Market Expansion?

The rise in occurrences of chronic kidney disease (CKD) is projected to accelerate the expansion of the intravenous iron drugs market. CKD is characterized by the slow deterioration of kidney function over time, which results in the kidneys’ incapacity to effectively eliminate waste and surplus fluids from the blood. The escalating prevalence of CKD can be attributed to increased incidences of diabetes and hypertension, which over time inflict damage on the kidneys. Intravenous iron drugs are beneficial for patients with CKD as they restore iron reserves, amend anemia, and boost hemoglobin concentrations, enhancing oxygen transport and minimizing the requirement for erythropoiesis-stimulating agents. For example, data reported by the Australian Institute of Health and Welfare, a government agency based in Australia, in June 2024 showed that death rates due to CKD surged by 4.2% in 2021 and by 6.2% in 2022. CKD accounted for roughly 22,000 deaths in Australia in 2022, corresponding to 11% of all deaths. Consequently, the rising prevalence of CKD is fuelling the expansion of the intravenous iron drugs market.

Which Segmentation Categories Are Highlighted In The Intravenous Iron Drugs Market Analysis?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Which Market Trends Are Expected To Define The Future Of The Intravenous Iron Drugs Market?

The key players in the intravenous iron drugs market are concentrating their efforts on the development of breakthrough therapies, such as IV iron replacement therapy. This innovative medical treatment, which allows iron to be delivered directly into the bloodstream through an intravenous infusion, aims to enhance efficacy, safety, and overall patient results, particularly for those with iron deficiency and anemia who are unable to effectively absorb or tolerate oral iron supplements. An example of such a development came in June 2023 when Daiichi Sankyo Company Limited, a renowned pharmaceutical firm based in Japan specializing in creative drug development and healthcare solutions, received approval from the U.S. Food and Drug Administration for Injectafer (ferric carboxymaltose injection). The medication, known for its ability to quickly restore iron levels in patients unresponsive to or incapable of tolerating oral iron supplements, has been approved for use in treating iron deficiency among adult heart failure patients classified as New York Heart Association class II/III, with the goal of enhancing their exercise capacity.

Which Players Are Shaping The Competitive Landscape Of The Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Regional Markets Are Emerging As Key Hubs For The Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#How Will the Anthrax Vaccine Market Evolve in Terms of Growth and Size by 2029?#_x000D_

The market size for intravenous iron drugs has experienced rapid expansion in recent years. Its projected growth trajectory sees it rising from a value of $3.44 billion in 2024, to $3.81 billion in 2025. This increase corresponds to a compound annual growth rate (CAGR) of 10.6%. The escalating prevalence of iron deficiency anemia, proliferating chronic diseases, a surge in healthcare spending, an aging populace, and an increasing occurrence of specific illnesses have been major factors contributing to this historical period growth._x000D_

_x000D_

The market for intravenous iron medications is projected to experience swift expansion in the ensuing years, catapulting to “$5.73 billion in 2029 with a compound annual growth rate (CAGR) of 10.8%. The anticipated growth during the forecast period could be due to government policies, advancements in the IV iron drugs sphere, rising demand for IV iron solutions, an uptick in research and developmental activities, and improved formulation and administration procedures. The forecast period is likely to witness developments such as advanced IV iron treatments, progress in drug formulation, a pivot towards more user-friendly IV iron treatments, strategic alliances, mergers and acquisitions, and breakthroughs in innovative drug delivery systems._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp_x000D_

_x000D_

#What factors are expected to fuel Anthrax Vaccine market growth in the coming years?#_x000D_

The escalating occurrence of contagious ailments is predicted to boost the anthrax vaccine market’s expansion. Contagious diseases are health conditions triggered by harmful microorganisms, inclusive of bacteria, viruses, parasites, or fungi. These diseases can transmit directly or indirectly between individuals, often leading to symptoms that vary in severity, sometimes leading to death, influenced by the pathogen and the person’s immune reaction. The rising occurrence of infectious diseases stems from demographic shifts worldwide, urbanization, environmental and land use changes, as well as alterations in human behavior. The anthrax vaccine is primarily employed to defend against anthrax and research is currently investigating its potential for wider use in warding off other infectious diseases through its immunogenic attributes and versatility. For example, the US-based nonprofit organization, the Council on Foreign Relations reported in February 2023 that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Additionally, across the globe, zoonoses result in 2.7 million human deaths and 2.5 billion instances of illness every year. Hence, the escalating occurrence of diseases is propelling the anthrax vaccine market’s growth._x000D_

_x000D_

_x000D_

The intravenous iron drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types_x000D_

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran _x000D_

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex _x000D_

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose _x000D_

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate_x000D_

_x000D_

#What Upcoming Trends Are Expected To Impact The Anthrax Vaccine Market Globally?#_x000D_

Prominent firms in the intravenous iron drugs market are putting their efforts into developing innovative therapies such as intravenous (IV) iron replacement therapy. They aim to enhance its effectiveness, safety, and influence on patient results. Intravenous (IV) iron replacement therapy is a medical procedure which administers iron directly into the bloodstream via an intravenous drip. This therapy is used to address iron deficiency and anemia, especially in individuals who are unable to adequately absorb or tolerate oral iron supplements. In June 2023, for instance, the U.S. Food and Drug Administration (FDA) gave approval to Daiichi Sankyo Company Limited, a pharmaceutical company based in Japan that is known for its inventive drug development and healthcare solutions. They received approval for Injectafer (ferric carboxymaltose injection), a treatment for iron deficiency in adults with heart failure who are categorized as New York Heart Association class II/III to boost their exercise capacity. Injectafer is a commonly used intravenous iron therapy renowned for rapidly restoring iron levels in patients who do not respond favorably or cannot bear oral iron supplements._x000D_

_x000D_

#What Are The Most Active Companies In The Anthrax Vaccine Market Today?#_x000D_

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation _x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report_x000D_

_x000D_

#Which Regional Markets Are Attracting The Most Investment In Anthrax Vaccine?#_x000D_

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has The Intravenous Iron Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_

The market size for intravenous iron drugs has seen a swift increase in recent years. There will be growth from $3.44 billion in 2024 to $3.81 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. Factors contributing to this growth in the past years include an increase in iron deficiency anemia cases, escalation in chronic diseases, a rise in healthcare expenditures, an aging population, and a greater incidence of the diseases they aim to treat._x000D_

_x000D_

The market size for intravenous iron medications is anticipated to witness rapid expansion in the coming years. The market is projected to reach $5.73 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.8%. The forecasted growth can be linked to governmental actions, advancements in research and development within the IV iron drug sector, heightened demand for intravenous iron treatments, an uptick in R&D activities, as well as enhancements in the formulation and administration. The anticipated trends in the forecast period include innovative intravenous iron therapies, progress in drug development, a shift in preference for more user-friendly iv iron therapies, deliberate collaborations, partnerships and procurements, and breakthroughs in novel drug delivery systems._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp_x000D_

_x000D_

#What Are the Primary Drivers Supporting the Market Growth of the Intravenous Iron Drugs Market?#_x000D_

The escalating prevalence of chronic kidney disease (CKD), marked by the slow and progressive decline in kidney function, is anticipated to spur the expansion of the intravenous iron drugs market. Rising instances of conditions such as diabetes and hypertension, which progressively harm the kidneys over time, are largely responsible for the spike in CKD rates. Intravenous iron medicines play a critical role in managing CKD by replenishing depleted iron resources, rectifying anemia, and elevating hemoglobin concentrations, thereby upgrading oxygen transport while simultaneously diminishing the necessity for erythropoiesis-stimulating agents. Notably, a rise of 4.2% in 2021 and 6.2% in 2022 was reported in CKD mortality rates by the Australian Institute of Health and Welfare, a government agency in Australia, in June 2024. Approximately 22,000 deaths in Australia were attributable to CKD in 2022, constituting around 11% of total mortality. As such, the escalating prevalence of chronic kidney disease (CKD) is propelling the growth trajectory of the intravenous iron drugs market._x000D_

_x000D_

#Which Primary Segments of the Intravenous Iron Drugs Market Are Driving Growth and Industry Transformations?#_x000D_

The intravenous iron drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types_x000D_

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases_x000D_

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy_x000D_

_x000D_

Subsegments:_x000D_

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran _x000D_

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex _x000D_

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose _x000D_

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp_x000D_

_x000D_

#Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Intravenous Iron Drugs Market?# Market?#_x000D_

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Are the Most Significant Market Trends in the Intravenous Iron Drugs Market?#_x000D_

Firms leading the intravenous iron drug market are placing emphasis on creating novel treatments, including intravenous (IV) iron replacement therapy, to boost safety, performance, and patient results. Intravenous (IV) iron replacement therapy is a clinical process that introduces iron into the bloodstream through an IV infusion, targeting iron inadequacy and anemia, primarily in patients who can’t properly absorb or can’t endure oral iron supplements. In June 2023, for instance, the U.S. Food and Drug Administration (FDA) agreed to the use of Injectafer, a ferric carboxymaltose injection produced by the Japan-based pharmaceutical firm Daiichi Sankyo Company Limited, known for its innovative drug development and healthcare services. This was aimed at treating iron deficiency in adult heart failure patients who fall under the New York Heart Association class II/III, with the goal of improving their exercise capacities. Injectafer has received wide acclaim as an intravenous iron therapy for quickly restoring iron levels in patients unresponsive to or unable to tolerate oral iron supplements._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report_x000D_

_x000D_

#What Parameters Are Used to Define the Intravenous Iron Drugs Market?#_x000D_

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, especially in patients who cannot tolerate or do not respond adequately to oral iron supplements. These drugs work by rapidly increasing iron levels, facilitating hemoglobin production, and improving oxygen transport, alleviating symptoms such as fatigue and weakness._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Intravenous Iron Drugs Market Size Changed, over the years?

In recent years, the market for intravenous iron medications has seen a substantial increase in size. Its growth is projected to continue, with an increase from $3.44 billion in 2024 to $3.84 billion in 2025, representing a compound annual growth rate (CAGR) of 11.6%. Factors contributing to the growth during the historic period include the growing prevalence of iron deficiency anemia, an increase in chronic illnesses, heightened healthcare expenditure, an aging global demographic, and a rise in the occurrence of related diseases.

How Much Will the Intravenous Iron Drugs Market Be Worth in 2029?

The market size for intravenous iron medications is predicted to experience significant expansion in the coming years. It is estimated to reach $5.86 billion by 2029, with a compound annual growth rate (CAGR) of 11.2%. The projected growth in this period can be attributed to several factors such as government initiatives, enhanced research and development within the IV iron drugs sector, a rise in demand for intravenous iron treatments, an increase in research and development programs, and progress in administration and formulation techniques. Key trends anticipated during this forecast period include the development of advanced intravenous iron treatments, breakthroughs in drug development, a movement towards more convenient IV iron therapies, strategic collaborations, partnerships and acquisitions, and innovative new drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

Which is the Largest Company in the Intravenous Iron Drugs Market?

Major companies operating in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy’s Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation

What Are the Main Market Drivers in the Intravenous Iron Drugs Industry?

The intravenous iron drugs market is projected to expand due to the rising prevalence of chronic kidney disease (CKD). CKD is characterized by the progressive loss of kidney function, resulting in the organ’s inability to properly eliminate waste and excess fluid from the blood. The surge in CKD cases can be mainly attributed to the increased incidence of diabetes and hypertension, both of which lead to kidney damage over time. Intravenous iron medications aid CKD patients by restoring iron levels, rectifying anemia, and raising hemoglobin levels, thereby improving oxygen transportation and minimizing the need for erythropoiesis-stimulating agents. For example, the Australian Institute of Health and Welfare, a governmental agency based in Australia, reported a 4.2% increase in CKD mortality in 2021 and a 6.2% rise in 2022. In the year 2022, CKD accounted for approximately 22,000 fatalities in Australia, representing 11% of all reported deaths. Therefore, the escalating cases of CKD is fueling the growth of the intravenous iron drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

How Is the Intravenous Iron Drugs Market Segments Structured?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

What Strategic Trends Are Transforming the Intravenous Iron Drugs Market?

Leading firms in the intravenous iron drugs market are prioritizing the generation of novel therapies such as intravenous (IV) iron replacement therapy, with the intention of enhancing effectiveness, safety, and patient results. This therapy, which delivers iron directly into the bloodstream via an IV drip, is used to manage iron deficiency and anemia, predominantly in patients who struggle to adequately absorb or tolerate oral iron supplements. Daiichi Sankyo Company Limited, an innovative pharmaceutical and healthcare solutions company based in Japan, revealed in June 2023, that the U.S. Food and Drug Administration (FDA) had given the green light for Injectafer (ferric carboxymaltose injection) to be used in treating adults with heart failure classified as New York Heart Association class II/III, for the purpose of improving exercise capacity. Injectafer is noted for being a widely embraced intravenous iron therapy due to its ability to promptly restore iron levels in patients who cannot absorb or tolerate oral iron supplements effectively.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

Which Global Regions Offer the Highest Growth in the Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430

This Report Delivers Insight On:

1. How big is the intravenous iron drugs market, and how is it changing globally?

2. Who are the major companies in the intravenous iron drugs market, and how are they performing?

3. What are the key opportunities and risks in the intravenous iron drugs market right now?

4. Which products or customer segments are growing the most in the intravenous iron drugs market?

5. What factors are helping or slowing down the growth of the intravenous iron drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 30% off on our Global Market Reports with code ONLINE30 – Hurry, limited time offer!

How Has The Intravenous Iron Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?

In recent times, the market size for intravenous iron drugs has experienced significant growth. Expected to increase from $3.44 billion in 2024 to $3.84 billion in 2025, the market will embrace a compound annual growth rate (CAGR) of 11.6%. Factors that contributed to the growth in the historical period include the rising instances of iron deficiency anemia and chronic diseases, the growth in healthcare expenditure, the aging demographic, and the escalating occurrence of targeted illnesses.

The market for intravenous iron medications is anticipated to experience a significant expansion in the coming years, surging to a value of $5.86 billion by 2029 with a compound annual growth rate (CAGR) of 11.2%. This anticipated growth during the projected period can be credited to factors such as governmental policies, advancements in the domain of IV iron medications, increased demand for these medicines, a rise in research and development activities, and enhancements in dispensation and composition. Furthermore, the major trends to be expected during the forecast period are inclusive of advanced intravenous iron treatments, progress in drug development, a transition towards more user-friendly iv iron therapies, strategic collaborations, partnerships and acquisitions, and innovative technologies in new drug delivery systems.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23430&type=smp

What Are the Core Growth Drivers Propelling the Intravenous Iron Drugs Market Forward?

The rise in cases of chronic kidney disease (CKD) is anticipated to drive the expansion of the intravenous iron drugs market in the future. CKD involves a gradual decline in kidney function over time, resulting in a compromised ability of the kidneys to effectively remove waste and excess fluids from the bloodstream. The escalating incidence of CKD can be attributed to increasing diabetes and hypertension rates that inflict long-term damage to the kidneys. Intravenous iron medications benefit CKD patients by replenishing deficient iron supplies, rectifying anemia, and boosting hemoglobin levels, thus augmenting oxygen transport and alleviating the requirement for erythropoiesis-stimulating agents. For example, as per the Australian Institute of Health and Welfare, a government organization based in Australia, mortality rates due to CKD elevated by 4.2% in 2021 and 6.2% in 2022. In 2022, CKD accounted for approximately 22,000 fatalities in Australia, constituting 11% of all deaths. Consequently, the escalating incidence of CKD is propelling the growth of the intravenous iron drugs market.

What Segment Types Define the Intravenous Iron Drugs Market Structure?

The intravenous iron drugs market covered in this report is segmented –

1) By Product Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types

2) By Indication: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Diseases

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran

2) By Iron Sucrose: Standard Iron Sucrose Injection, Iron Sucrose Complex

3) By Ferric Carboxymaltose: Single-Dose Ferric Carboxymaltose, Multiple-Dose Ferric Carboxymaltose

4) By Other Product Types: Ferumoxytol, Ferric Derisomaltose, Sodium Ferric Gluconate

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23430&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Intravenous Iron Drugs Market?

North America was the largest region in the intravenous iron drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous iron drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Intravenous Iron Drugs Market?

Leading enterprises in the intravenous iron drugs market are concentrating on pioneering novel therapies, including intravenous (IV) iron replacement therapy, with the aim of enhancing efficacy, safety and outcomes for patients. The said therapy is a medical procedure that provides iron straight into a patient’s bloodstream via intravenous infusion, targeting iron deficiency and anemia, specifically for individuals who can’t adequately absorb or endure oral iron supplements. As an example, in June 2023, a pharmaceutical firm from Japan, Daiichi Sankyo Company Limited, known for its groundbreaking drug development and healthcare solutions, declared that Injectafer (ferric carboxymaltose injection), used for treating iron deficiency in adult patients with heart failure classified as New York Heart Association class II/III to elevate their exercise capacity, had received approval by the U.S. Food and Drug Administration (FDA). Injectafer has a great reputation as an intravenous iron therapy for effectively restoring iron levels in patients who either do not respond well or are intolerant to oral iron supplements.

View the full report here:

https://www.thebusinessresearchcompany.com/report/intravenous-iron-drugs-global-market-report

What Is the Definition of the Intravenous Iron Drugs Market?

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, especially in patients who cannot tolerate or do not respond adequately to oral iron supplements. These drugs work by rapidly increasing iron levels, facilitating hemoglobin production, and improving oxygen transport, alleviating symptoms such as fatigue and weakness.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23430

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model